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INTRODUCTION
Aspirin-exacerbated respiratory disease (AERD) is character-
ized by asthma, the presence of polyps in nasal passages, and 
sensitivity to aspirin and other non-steroidal anti-inflammato-
ry drugs (NSAIDs).
1 Although previous research has attributed 
AERD pathophysiology to inhibition of the cyclooxygenase-2 
(COX-2) pathway, resulting in decreased synthesis of prostaglan-
din E2 (PGE2) and overproduction of cys-leukotrienes (cysLTs),
2 
recent reports have suggested that several genes may play a 
predisposing role, implicating other pathways in AERD patho-
genesis; these include major histocompatibility complex (MHC), 
class II, DP beta 1 (HLA-DPB1), solute carrier family 6 (neu-
rotransmitter transporter, betaine/GABA) member 12 (SL-
C6A12), complementary component 6 (C6), D-tyrosyl-tRNA 
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deacylase (DTD1), and emilin/multimerin domain-containing 
protein 2 (EMID2).
3-7
The MHC, a group of genes that determines the immune re-
sponse to pathogens, is central to the activation of the innate 
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Purpose: The human WD repeat-containing protein 46 (WDR46; also known as C6orf11), located at the disease-relevant centromere side of the 
class II major histocompatibility complex region, is hypothesized to be associated with risk of aspirin-exacerbated respiratory disease (AERD) as well 
as a decline in forced expiratory volume in the first second (FEV1), an important diagnostic marker of asthma.  Methods:  To investigate the associ-
ation between WDR46 and AERD, five single-nucleotide polymorphisms (SNPs) were genotyped in 93 AERD cases and 96 aspirin-tolerant asthma 
controls of Korean ethnicity. Three major haplotypes were inferred from pairwise comparison of the SNPs, and one was included in the association 
analysis. Differences in the frequency distribution of WDR46 SNPs and haplotype were analyzed using logistic and regression models via various 
modes of genetic inheritance.  Results:  Depending on the genetic model, the logistic and regression analyses revealed significant associations be-
tween rs463260, rs446735, rs455567, rs469064, and WDR46_ht2 and the risk of AERD (P=0.007-0.04, Pcorr=0.01-0.04) and FEV1 decline after aspi-
rin provocation (P=0.006-0.03, Pcorr=0.01-0.03). Furthermore, functional analysis in silico showed that the G>A allele of rs463260 located in the 5’ 
untranslated region potentially matched a nucleotide sequence within an upstream open reading frame of WDR46.  Conclusions:  These findings 
show for the first time that WDR46 is an important genetic marker of aspirin-induced airway inflammation and may be useful for formulating new 
disease-management strategies.
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immune system. The human WD repeat-containing protein 46 
(WDR46, also called C6orf11 and BING4; NM_005452) gene is 
located on chromosome 6p21.3 at the centromere side of the 
class II MHC region, and encodes a protein that is 610 amino 
acids in length
8 that shows homology to Saccharomyces cerevi-
siae and Caenorhabditis elegans proteins.
9 In particular, WDR46 
contains a class I type aminotransferase pyridoxal phosphate 
attachment site motif, a class I aminoacyl-tRNA synthetase ad-
enylate binding site motif, and G-beta (WD40) repeats found in 
the β-subunits of G-proteins.
10 A previous study of metastatic 
cancer patients reported high expression levels of WDR46 
mRNA in melanoma cell lines, which correlated with lympho-
cyte recognition, resulting in secretion of additional cytokines. 
Furthermore, one of the MHC class II genes, HLA-DPB1, is a 
genetic marker for AERD in the Korean population, suggesting 
that WDR46 may be a candidate gene for disease susceptibility. 
However, little of the structure of WDR46 has been reported, 
and its function remains unknown.
Because genes at the centromere end of the MHC are often 
associated with several human diseases including asthma,
3 and 
recruitment and activation of T-lymphocytes with increased cy-
tokine production has been implicated in aspirin-induced air-
way inflammation,
11,12 WDR46 is hypothesized to be associated 
with the risk of AERD. Thus, we conducted an association anal-
ysis on a Korean asthma cohort.
MATERIALS AND METHODS
Study patients
Asthma patients enrolled in nine hospitals in Korea affiliated 
with the Asthma Genome Research Center were recruited. Di-
agnosis of asthma and tests measuring total immunoglobulin E 
(IgE), atopy, and individuals’ reactions to inhalant allergens 
were performed. Oral aspirin challenge (OAC) was performed 
using increasing doses.
13,14 Briefly, patients with a history of as-
pirin hypersensitivity were given 30 mg orally. Respiratory and 
nasal symptoms, blood pressure, external signs (urticaria and 
angio-oedema), and FEV1 were documented every 30 minutes 
for 1.5 hours. In the absence of any symptom or sign suggesting 
an adverse reaction after 1.5 hours, increasing aspirin doses (60, 
100, 300, and 400 mg) were administered until the patient de-
veloped a reaction; subsequently the same measurements were 
repeated hourly. Those with no history of aspirin hypersensitiv-
ity were started on 100 mg aspirin, which was increased to 200, 
350, and 450 mg until a reaction developed. If no reaction oc-
curred 4 hours after the final dose, the test was deemed nega-
tive. Aspirin-induced bronchospasm, reflected by a decline (%) 
in FEV1, was calculated as the pre-challenge FEV1 minus the 
post-challenge FEV1, divided by the pre-challenge FEV1. OAC 
reactions were categorized into three groups: (1) a 15% or great-
er decrease in FEV1 or nasal reactions (AERD), (2) less than a 
15% decrease in FEV1 without naso-ocular or cutaneous reac-
tions (aspirin-tolerant asthma [ATA]), or (3) less than a 15% de-
crease in FEV1 with cutaneous reactions (aspirin-induced urti-
caria). Written informed consent was obtained from each pa-
tient, and the study protocol was approved by the Institutional 
Review Board of each participating hospital.
Selection and genotyping of single-nucleotide polymorphisms
Using the tagging approach, candidate single-nucleotide poly-
morphisms (SNPs) in WDR46 were screened from the Interna-
tional HapMap database (version release #27; http://www.hap-
map.org) based on linkage disequilibrium (LD) status in the 
Asian population (Han Chinese and Japanese) and location 
within the gene. Genotypes were derived by TaqMan assay
15 us-
ing an ABI prism 7900HT sequence detection system (Applied 
Biosystems, Foster City, CA, USA). Evaluation of LDs between 
screened SNPs was carried out using the Haploview software,
16 
and SNPs with a minor allele frequency (MAF)>0.05 and those 
tagged because several polymorphisms had an LD>0.98, were 
selected for association analysis.
Statistical analyses
The association between differences in genotype frequency 
distribution of WDR46 variation and the risk of AERD and air-
way obstruction was analyzed according to previous methods.
7 
The statistical power of single associations was determined us-
ing the Power for Genetic Association Analyses software,
17 and 
multiple testing corrections were calculated using the effective 
number of independent marker loci (Meff), that accounts for 
the eigenvalue spectral decomposition (SpD) of all of the geno-
types represented in the correlation matrix extracted from the 
SNPSpD program.
18 Furthermore, functional analyses of WDR46 
SNPs were carried out in silico using the UTRScan program
19 
and the European Molecular Biology Laboratory-European 
Bioinformatics Institute (EMBL-EBI) splice site prediction soft-
ware (http://www.ebi.ac.uk/asd-srv/wb.cgi?method=2).
RESULTS
Categorization and clinical characteristics
Based on individual reactions to aspirin, the asthma patients 
(n=189) were stratified into 93 AERD cases (males, 32; females, 
61) and 96 ATA controls (males, 24; females, 72) (Table 1). The 
aspirin-induced decrease in FEV1 (AERD, 23.61 vs. ATA, 0.94), 
positivity rate of aspirin side effects including external signs of 
urticaria and angioedema (AERD, 26.67% vs. ATA, 8.42%), and 
positive history of aspirin intolerance (AERD, 63.86% vs. ATA, 
29.27%) were significantly different between cases and controls 
(P<0.0001; Table 1). No significant differences for any other di-
agnostic factors were observed.
Distribution of WDR46 variants
With high rates of concordance in duplicates (>99%), 5 WDR46 WDR46 Polymorphism and AERD
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Table 1.  Clinical profiles of the study patients
AERD (n=93) ATA (n=96) P value 
Age, mean (range) 44.39 (17-73) 45.79 (15-77) 0.497
Onset age, mean (range) 38.01 (0-70) 37.99 (5-73) 0.995
BMI (kg/m
2) 23.47±3.18 24.41±3.29 0.049
Peripheral eosinophil count* 80,734.1±
48,861.5
36,429.1±
33,900.2
0.060
FVC %, predicted 89.90±14.74 87.76±12.80 0.293
FEV1 %, predicted 86.63±16.74 88.26±17.04 0.509
PC20, methacholine (mg/mL) 4.23±7.18 3.04±4.27 0.193
Total IgE (IU/mL) 321.65±623.31 309.54±426.04 0.878
FEV1 decline after aspirin  
challenge
23.61±14.48 0.94±2.76 0.001
Sex (male/female) 32/61 24/72 0.156
Ex-smoker/current smoker (%) 15.63/9.38 6.45/12.90 0.219
Atopy rate (%) 61.46 56.99 0.532
Adverse reaction to aspirin (%) 26.67 8.42 0.001
Positive rate of nasal polyp (%) 63.86 29.27 0.001
Values are mean±SE.
AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; 
BMI, body mass index.
*Blood eosinophil (%): 6.29±5.80 (AERD group), 4.88±4.19 (ATA group).
Figure.  Physical map, linkage disequilibrium, and haplotypes of WDR46. (A) Schematic gene map and single-nucleotide polymorphisms (SNPs) of WDR46 on chro-
mosome 6p21.3 (10.11 kbp). Black blocks represent coding exons and white blocks represent 5’ and 3’ untranslated regions. The first base of translation sites are de-
noted as nucleotide +1. SNPs in absolute linkage are indicated by brackets (r
2=1). (B) LD coefficient (|D’|) among WDR46 SNPs in a Korean population. (C) Haplotypes 
of WDR46.
otyped. The genotype counts and MAFs of each SNP are sum-
marized in Supplementary Table S1. Furthermore, none of the 
variants deviated from the Hardy-Weinberg Equilibrium (HWE). 
Pairwise comparison of the genotyped SNPs showed a tight LD 
in the study population (Figure B) and produced three major 
haplotypes (MAF>0.05; Figure C). However, because WDR46_
ht1 and WDR46_ht3 were equivalent to some SNPs, only 
WDR46_ht2 was included in the association analysis.
Association analysis of WDR46 variants with a risk for AERD 
and FEV1 decline
The results of logistic analysis controlling for age, sex, smoking 
status, atopy, and body mass index (BMI) revealed that the ma-
jority of the analyzed WDR46 variants (rs463260, rs446735, 
rs455567, rs469064, and WDR46_ht2) were associated with a 
risk for AERD (P=0.007-0.04, odds ratio [OR]=1.88-1.89 de-
pending on the genetic model; Table 2). The association signals 
maintained significance under co-dominant and recessive 
models after multiple testing corrections (Pcorr=0.01-0.04; Meff=
2.2767; Table 2).
The results of regression analysis after adjustment for age, sex, 
smoking status, atopy, and BMI showed a significant association 
between a similar set of WDR46 variants (rs463260, rs446735, 
rs455567, rs469064, and WDR46_ht2) and decreased FEV1 in 
asthma patients (P=0.006-0.03 under co-dominant and domi-
nant models; Table 3), even after multiple comparisons (Pcorr=
0.01-0.03 in co-dominant and dominant models; Table 3).
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SNPs, rs463260 in the 5’ untranslated region (UTR), rs466384 in 
the exon, and rs446735, rs455567, and rs469064 in the introns 
(Figure A and Supplementary Table S1), were successfully gen-Pasaje et al.
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Functional analyses in silico 
Functional estimation of SNPs in intronic regions of WDR46 
revealed that none of the analyzed variants act as branch point 
sites for alternative splicing (data not shown). However, results 
of another computer simulation analysis showed that the se-
quence containing the G>A allele of rs463260 located in the 5’ 
UTR matched a nucleotide sequence within a UTRSite signal of 
WDR46, more specifically, an upstream open reading frame 
(uORF; Supplementary Table S2).
DISCUSSION
Although ample progress has been made in understanding 
the pathogenesis of AERD, the observed association between it 
and genes that were originally thought to play no relevant role 
in aspirin-induced airway bronchospasm suggests that the ex-
act mechanisms of AERD development remain to be elucidat-
ed. The current findings provide important insight into the eti-
ology of aspirin-hypersensitive asthma by reporting, for the first 
time, a significant association between the WDR46 variants 
rs463260, rs446735, rs455567, rs469064, as well as the major 
haplotype WDR46_ht2, and the risk of AERD. Furthermore, 
with a marginal increase in association signals, similar variants 
were found to induce significant decreases in FEV1, an impor-
tant diagnostic marker of respiratory obstruction, among AERD 
patients compared to ATA controls. The reported association 
maintained significance under the strict criteria of multiple 
testing corrections. In particular, the rs463260 polymorphism 
exhibited a consistently robust association signal with the risk 
of AERD (P=0.007, Pcorr=0.01 in a co-dominant model) and 
FEV1 (P=0.005, Pcorr=0.01 in a co-dominant model) decline 
even after multiple comparisons. The association of WDR46 
with risk of AERD was suggested via co-dominant and domi-
nant modes of genetic inheritance in a Korean population.
Despite the dearth of previous reports, the positioning of the 
WDR46 gene in the MHC region is suggested to play a role in 
AERD development as well as decreased FEV1 due to aspirin 
ingestion. In further analysis, a uORF was detected in the 5’ UTR 
of WDR46 and the G>A allele of the rs463260 polymorphism 
was found within the start and end positions of the UTRSite sig-
nal. The predicted uORF in the 5’ UTR is speculated to be among 
the nine potential ORFs previously identified within WDR46.
8 
Although the role of uORFs is not yet fully understood, the 5’ 
UTR harbors cis/trans-acting elements that play a crucial role 
Table 2.  Association analysis of variation in WDR46 with AERD
SNP/
Haplotype
MAF HWE
* Co-dominant Dominant Recessive Statist 
ical 
power AERD ATA AERD ATA OR (95% CI) P
† Pcorr
‡ OR (95% CI) P
† Pcorr
‡ OR (95% CI) P
† Pcorr
‡
rs463260 0.374 0.250 0.561 0.586 1.88 (1.19-2.99) 0.007 0.010 1.89 (1.04-3.42) 0.040 >0.050 3.71 (1.25-11.00) 0.020 0.040 33.52
rs446735 0.366 0.255 0.799 0.892 1.74 (1.10-2.75) 0.020 0.030 1.86 (1.03-3.36) 0.040 >0.050 2.58 (0.92-7.22) 0.070 - 35.19
rs466384 0.082 0.068 0.597 0.365 1.21 (0.56-2.58) 0.630 - 1.27 (0.54-2.96) 0.590 - 0.98 (0.06-16.66) 0.990 - 20.86
rs455567 0.368 0.255 0.764 0.892 1.77 (1.12-2.79) 0.020 0.030 1.89 (1.04-3.42) 0.040 >0.050 2.65 (0.94-7.42) 0.060 - 34.97
rs469064 0.361 0.250 0.904 0.586 1.78 (1.12-2.85) 0.020 0.030 1.85 (1.02-3.36) 0.040 >0.050 2.93 (0.97-8.84) 0.060 - 34.95
WDR46_ht2 0.283 0.182 0.687 0.415 1.86 (1.12-3.10) 0.020 0.030 1.79 (0.98-3.27) 0.060 - 5.42 (1.09-26.93) 0.040 >0.050 51.74
Logistic analysis controlling for age, sex, smoking status, atopy, and body mass index.
*P values of Hardy-Weinberg equilibrium (HWE).
†P values at 0.05 levels of significance. 
‡P values after multiple testing corrections (Meff=2.2767). Significant values are shown in bold.
WDR46, human WD repeat-containing protein 46; AERD, aspirin-exacerbated respiratory disease; SNP, single-nucleotide polymorphism; MAF, minor allele frequen-
cy; ATA, aspirin-tolerant asthma; OR, odds ratio; CI, confidence interval.
Table 3.  Regression analysis of variation in WDR46 with decrease in FEV1 rate due to aspirin ingestion
SNP C/C C/R R/R
Co-dominant Dominant Recessive
P
* Pcorr
† P
* Pcorr
† P
* Pcorr
†
rs463260 90 (9.11±12.60) 78 (13.90±17.31) 19 (18.03±17.09) 0.005 0.010 0.010 0.020 0.050 -
rs446735 91 (9.21±12.56) 79 (14.39±17.15) 19 (16.37±17.68) 0.010 0.020 0.010 0.020 0.190 -
rs466384 161 (11.44±14.79) 24 (16.23±19.09) 2 (7.70±17.39) 0.370 - 0.260 - 0.680 -
rs455567 90 (9.11±12.60) 78 (14.30±17.25) 19 (16.37±17.68) 0.010 0.020 0.010 0.020 0.180 -
rs469064 90 (9.11±12.60) 79 (13.91±17.26) 17 (18.18±17.85) 0.006 0.010 0.010 0.020 0.080 -
WDR46_ht2 110 (10.01±13.72) 66 (14.30±17.78) 10 (18.59±14.52) 0.020 0.030 0.030 >0.050 0.110 -
Co-dominant, dominant, and recessive models of regression analysis controlling for age, sex, smoking status, atopy, and body mass index.
C/C, C/R, and R/R refer to major homozygote, heterozygote, and minor homozygote, respectively.
*P values at 0.05 levels of significance. 
†P values after multiple testing corrections (Meff=2.2767). Significant values are shown in bold. WDR46 Polymorphism and AERD
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in the regulation of gene expression by mediating translation 
efficiency and mRNA stability.
19 Thus, the results of our in silico 
analyses suggest that the relevance of the significant SNP, 
rs463260G>A, in AERD susceptibility may be a manifestation 
of cis-regulated gene expression.
Examination of expressed sequence tags suggested the pres-
ence of alternative splicing within the WDR46 transcript.
9 Al-
though polymorphisms located in the non-coding intronic re-
gions of the gene were originally thought to have no role in pro-
tein function, these intronic variants may also affect alternative 
splicing, splicing efficiency, or mRNA turnover as has been re-
ported for other disease-causing genes.
20 Thus, an in silico anal-
ysis was carried out to functionally characterize the intronic 
WDR46 polymorphisms. None of the analyzed variants were 
predicted to be branch point sites for alternative splicing, refut-
ing our hypothesis.
Although the results from power calculations revealed a 
35.24% average statistical power to detect effect sizes with the 
current sample (Table 2), indicating insufficient sample size, 
the allele frequency of the analyzed variants in our Korean pop-
ulation was similar to that of other Asian ethnic groups (Japa-
nese and Han Chinese; Supplementary Table S1). However, 
while our findings successfully elucidated the association of 
WDR46 variation with aspirin-induced airway inflammation, 
the lack of an in-depth molecular investigation may be a limita-
tion of this preliminary report. Furthermore, differences in the 
effects of genetic variation with regard to geographical location 
and/or ethnicity should also be taken into consideration. The 
present findings would, therefore, benefit from future studies 
addressing these limitations. Moreover, the advent of next-gen-
eration sequencing (NGS) with one-base ultra-resolution and 
high-density chip microarrays makes it possible to investigate 
the association of rare WDR46 variants with the risk of AERD.
In conclusion, our data provide convincing evidence that 
WDR46 variants are associated with the risk for both AERD and 
a relevant phenotype, FEV1 decline, in a Korean asthma cohort. 
Because the function of WDR46 in human diseases remains to 
be elucidated, our data represent a marked contribution to the 
knowledge on the role of this gene in airway inflammation.
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Supplementary Table 1.  Alleles and genotype distribution of WDR46 SNPs
SNP Position Allele Genotype Heterozygosity
MAF
Korean Caucasian
* Chinese
* Japanese
* African
*
rs463260 5' UTR G>A G
90
AG 
78
A
19
0.428 0.310 0.500 0.350 0.330 0.714
rs446735 Intron 8 T>G T
91
GT
79
G
19
0.427 0.310 0.500 0.358 0.332 0.719
rs466384 Exon 10 T>C T
161
CT
24
C
2
0.139 0.075 - - - -
rs455567 Intron 10 C>T C
90
CT
78
T
19
0.428 0.310 0.500 0.358 0.329 0.732
rs469064 Intron 10 G>T G
90
GT
79
T
17
0.423 0.304 0.495 0.354 0.324 0.246
SNP, single-nucleotide polymorphism; MAF, minor allele frequency; UTR, untranslated region.
*Data taken from the International HapMap database (version: release #28; http://www.hapmap.org).
Supplementary Table 2.  UTRScan output for rs463260
SNP Input sequence length* UTRSite signal Start and end positions of signal Matched nucleotide sequence
rs463260G>A 361bases Upstream  
Open Reading 
Frame
85-348 ATG 
GCACCTAGAGAGCTTCATACCTGGTACGCTGCTGAT
TGGATGAAGGACAGAGGGCTTCCGGGAGTTTTCAAG
CCGACTGTGTGGCAGCTGAGA[G/A]GAGTTTTGCACG
TGGATCGCCGTTCGGGTGGGCGAGATGGAGACAGCC
CCCAAGCCGGGCAAGGATGTCCCGCCCAAGAAAGA
CAAACTTCAGACCAAGAGAAAGGTAGAGGCCTCCCT
GGGTGGGAAACGAAGTTTTTAGCTGTGGGGTCGGGG
GGCGGGGCG TGA
Nucleotide sequence for the UTRsite signal is predicted using the UTRScan program (http://itbtools.ba.itb.cnr.it/utrscan).
*FASTA sequence taken from National Center for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov).